Jan 2006 - Present17 years 2 months. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of. Stock ticker symbol (e.g. Description. Nature. J Biol Chem. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. 2003 Sep 26;278(39):37926-36. On behalf of the management team, I am pleased to welcome Ms. Harrison to ITI. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. Phone Number +4989208047700. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. Active, Closed, Last funding round type (e.g. Contact Email info@immunomet.com. CONTACT US. ITI-1001 is an alternative, cell-free approach to treating GBM. aanagnostou@immunomix.com We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in this tumor type and others. ITI-ID Candidate Multiple infectious diseases. Home - Immunomic Therapeutics Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body's natural biochemistry to develop vaccines that have the . The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive. These factors are currently under intense focus in the cancer immunotherapy landscape. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. SaaS, Android, Cloud Computing, Medical Device). Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform . Melody Carey Where the organization is headquartered (e.g. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . What is health insurance like at Immunomic Therapeutics. The company is developing three small molecule products; its lead development program, IMU-838, a selective . 301-968-3501 It is important to note that, while the mechanism of lysosomal targeting appears to focus on enhancing presentation of antigen to CD4+ T cells and producing a Th1 type CD4+ T cell response (an aspect missing in other platforms), the UNITE platform, as a whole, is believed to induce a broad immune response and can result in enhanced CD8+ T cell responses as well. Amy Conrad Leveraging our geographically precise solutions (GPS) platform, we are building a pipeline of tumor-activated cytokine and checkpoint inhibitor immunotherapies to treat cancer. Melissa Kemp immunomic therapeutics crunchbase. The first ITI oncology clinical program was born as a result of this decision and each subsequent asset in the pipeline represents a natural transition from this original point of entry into oncology. Company profile for HLB Co. Ltd. including key executives, insider trading, ownership, revenue and average growth rates. The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. Jan 30, 2015. Their LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in . Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . Contact Email info@immunic.de. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. ITI-3000 Merkel Cell Carcinoma - pDNA. In addition, ITI and HLB intend to establish an Asian Brain Cancer Research Center in Seoul that will bring together the worlds leading experts and cutting-edge science to advance research in the GBM field and to deploy ITI-1000 to the Asian population. ITI-1001 GBM - pDNA. Immunomic Therapeutics Strengthens Leadership Team with Appointment of It is one of the few malignancies for which incidence approximates prevalence, as patients almost always . Companies. News Releases | PharmaJet A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. Immunomic Therapeutics Announces Close of $61.3M Financing This is the Immunomic Therapeutics company profile. Immunomic Therapeutics, Inc. | LinkedIn Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bo dy's natural biochemistry to develop . They have a proven track record of success in Asia and share our commitment and passion for developing best-in-class therapies for cancer and other serious diseases, said Dr. William Hearl, CEO of Immunomic Therapeutics. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. Clin Cancer Res 2020;26:5297303, Batich K.A.,Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Rockville, Maryland, 20850, United States. ITI-3000 Merkel Cell Carcinoma - pDNA. In this way, ITIs vaccines (DNA or RNA) have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. Today, Brian Stamper, VP, Immunomic Therapeutics, will participate at #MTC's Annapolis Day 2023. ITI-ID Candidate Multiple infectious diseases. All content is posted anonymously by employees working at Immunomic Therapeutics. 301-968-3501, ITI Media: ITI maintains its headquarters in Rockville, Maryland. We provide a professional and challenging work environment . ITI-1001 GBM - pDNA. HLB also secured an option to make further investment into the company in the months ahead. April 23, 2020 04:00 PM Eastern Daylight Time. 028300.KR | HLB Co. Ltd. Company Profile & Executives - WSJ Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. We currently have 4 wholly-owned oncology programs, with our lead program in Phase 2 clinical studies for GBM. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. We are also collaborating with academic centers and biotechnology companies to study the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma. Immunomic Therapeutics (ITI) is a clinical stage biotechnology company pioneering investigational technologies that have the potential to alter how immunotherapy is used for cancer, allergies, and animal health. Working at Immunomic Therapeutics | Glassdoor 15010 Broschart Road Suite 250. This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. Headquarters Location. We are delighted to welcome Brian to the Immunomic team, said William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. No.93, Zhongyang Rd., Xindian Dist., New Taipei City 231, Taiwan. Immunomic Therapeutics, Inc. Su Y et al., CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model. Stemming from our UNITE Platform, Immunomic Therapeutics has developed a robust and deep pipeline focused on immunotherapeutics with an emphasis in treating and preventing many oncology indications by leveraging specific characteristics of a type of antigen. Mohan Karkada - Director of Research and Development - LinkedIn Hope versus experience in glioblastoma | Evaluate ITIs UNITE platform combines its core lysosomal targeting technology with novel formulation, delivery, and adjuvant complements. Be sure to include your name, the Job Code of the job you are interested in, and the accommodation you are seeking. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies, and animal health. ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. Su Y et al., Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I study. The company held a successful pre-IND meeting earlier this year for ITI-1001 and expects to be able to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) by the end of 2020. Additionally, our expanded capabilities allow us to work with our corporate partners to better understand and develop the manufacturing process and product testing assays. ITI-2000 provides an UNITE platform address for HPV+ cancers. Innovative Cellular Therapeutics (ICT) | LinkedIn Immunomic Therapeutics investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. mcarey@rxir.com Immunomic Therapeutics, Inc. | 2,335 followers on LinkedIn. Clin Cancer Res. Immunomic Therapeutics Stock Price, Funding, Valuation, Revenue Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. amy@juniper-point.com Prior to joining ITI, Mr. Stamper held director roles in manufacturing at Kite Pharma, a global biopharmaceutical company whose focus is cell therapy to treat and cure cancer. Immunomic Therapeutics - Overview, News & Competitors | ZoomInfo.com It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex . Seed, Series A, Private Equity), Alternate or previous names for the organization, Whether an Organization is for profit or non-profit, General contact email for the organization. Find More Contacts for ImmunoMet Therapeutics, Edit Lists Featuring This Company Section, Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer, ImmunoMet Therapeutics Appoints Vincent ONeill Chief Medical Officer, Health Care Companies With Less Than $1M in Revenue (Top 10K), Pharmaceutical Companies With Fewer Than 1000 Employees (Top 10K), Southern US Companies With Less Than $50M in Revenue (Top 10K). ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. We are a patient advocacy company that understands that patient enrollment in clinical trials is critical to advancements in medicine and patient treatment. Find More Contacts for Immunomic Therapeutics, Diversity Spotlight (US Headquarters Only). Edit Lists Featuring This Company Section, Immunomic Therapeutics to Present at Biotech Showcase 2023. Immunic Therapeutics - Crunchbase Company Profile & Funding 2006 Aug 15;177(4):2265-75. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleic acid-based immunotherapy today announced the appointment of Brian Stamper to Vice President, Cell Therapy Operations. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Mitchell D.A.,Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. Pay, Holidays and PTO appear to be very good. You will receive a reply to confirm the receipt of your application. Bard (Becton, Dickinson and Company). We have significant capabilities in molecular biology, including nucleic acid vaccine design, immunology, and tumor mouse modeling. Katie Pearce. Harnessing the immune system to achieve deep and durable clinical responses in cancer. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes.